FMC’s Rimisoxafen Classified Under HRAC Groups 12 and 32
FMC Corporation’s rimisoxafen has been classified by the Herbicide Resistance Action Committee under Groups 12 and 32, marking the first dual mode of action herbicide in the industry. It inhibits both phytoene desaturase and solanesyl diphosphate synthase pathways and FMC will begin regulatory submissions in key markets in 2026.
1. HRAC Classification Milestone
The Herbicide Resistance Action Committee has designated rimisoxafen as a dual mode of action herbicide under Groups 12 and 32, marking the first time in the committee’s history that a product combines two distinct inhibitory pathways. This recognition underscores the molecule’s novel approach to addressing herbicide resistance.
2. Dual Mode Mechanism Explored
Rimisoxafen simultaneously inhibits phytoene desaturase (PDS) and solanesyl diphosphate synthase (SDPS), disrupting two critical biochemical pathways in broadleaf weeds. This dual inhibition increases the barrier to resistance development in species like palmer amaranth and waterhemp.
3. Regulatory Submission Plans
FMC plans to submit regulatory dossiers for rimisoxafen in key global markets starting in 2026, progressing toward commercial launch in broadacre crops such as corn, soybean, cereals, pulses and sunflower. These filings represent the next phase in bringing the product to growers facing multi-resistant weed populations.
4. Portfolio and Market Impact
Rimisoxafen represents FMC’s third novel herbicide for regulatory submission following Isoflex® and Dodhylex™, strengthening its crop protection pipeline. The breakthrough classification enhances FMC’s competitive position by offering growers an advanced tool against economically damaging resistant weeds.